Partners

Akthelia Pharmaceuticals

BRIEF DESCRIPTION OF THE ORGANIZATION

Akthelia Pharma is an Icelandic late preclinical-stage immunotherapy firm, targetting major cancer and transplant challenges by mitigating neutropenic sepsis risk. This life-threatening complication from anticancer treatment, leading to up to 20% mortality excluding disease progression, results from neutrophil count reduction and GI integrity loss. We’ve innovated a patented approach backed by top KOLs to enhance GI tract immunity and integrity, effectively blocking bacterial translocation, the main causal pathophysiology. Our patents also pave the way for an out-licensing platform for various indications, creating a pipeline and lessening dilutive financing needs for our lead program.

WHAT IS YOUR ROLE IN THE PROJECT?

Lead molecule candidate optimisation, synthesis & shortlisting. Participate in all other work packages. Akthelia Pharmaceuticals will lead the first work package, which includes molecule candidate optimisation, synthesis & shortlisting. Akthelia’s expertise in therapeutic discovery and development will continue to guide and oversee the work undertaken in subsequent packages, from WP2 to WP8.

Researches

NAME
Egill Masson

POSITION
CEO

NAME
Sonja Srdanović

POSITION
R&D Manager Infections & Inflammation